Key Summary
- Novo Nordisk to unveil major obesity research at the European Congress, including new Wegovy data.
- Next-gen treatments in focus, including higher doses, pills, and the new CagriSema therapy.
- Strengthening its lead in weight loss care, especially for people with obesity and type 2 diabetes.
Pharma giant Novo Nordisk will present new clinical data and real-world evidence on its flagship weight loss drug Wegovy, women with obesity and the next generation weight loss treatments at the European Congress on Obesity (ECO), which will take place in Istanbul from 12 to 15 May.
The Danish multinational has the largest number of approved and pipeline glucagon-like peptide-1 (GLP-1) therapies, which is used to treat Type-2 diabetes and obesity.
The full data, 52 abstracts, span Wegovy (semaglutide 2.4 mg), higher-dose Wegovy (semaglutide 7.2 mg), Wegovy pill (oral semaglutide 25 mg), and CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg), an investigational first-in-class combination of a GLP-1 receptor agonist and a long-acting amylin analogue will be highlighted in its presentation proving itself as the scientific leader in obesity treatment.
Wegovy, popular for its ability to decrease excessive body weight has gained its approvals from the European Medicines Agency (EMA) and many other regulatory authorities, along with the US-based Food and Drug Administration’s (FDA) approval for reducing cardiovascular health risks.
CagriSema is being examined by Novo Nordisk as another effective adult weight loss treatment, especially for people with type 2 diabetes. Cagrisema is known for reducing appetite and calorie intake in people.
The presentation will be done in various categories such as Wegovy pill – oral semaglutide 25 mg (OASIS 4, ORION, OPTIC), and Wegovy – semaglutide 2.4 mg (SELECT).
Similarly, there are various other oral sessions prepared regarding Wegovy - semaglutide 7.2 mg (STEP UP).
